infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients.
Antimicrob agents chemother, v. 51, no. 6, p. 1905-1911, 2007.
HANCOCK, R. E. W.; CHAPPLE, D. S. Peptide antibiotics. Antimicrob Agents Chemother,
v. 43, no. 6, p. 1317-1323, 1999.
HANCOCK, R. E. W.; SPEERT, D. P. Antibiotic resistance in Pseudomonas aeruginosa:
mechanisms and impact on treatment. Drug resist Updat, v. 3, p. 247-255, 2000.
LANDMAN, D.; BRATU, S.; ALAM, M.; QUALE, J. Citywide emergence of Pseudomonas
aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob
Chemother, v. 55, p. 954-957, 2005.
LI, J.; NATION, R. I.; TURNIDGE, J. D.; MILNE, R. W.; COULTHARD, K.; RAYNER, C.
R.; PATERSON, D. L. Colistin: the re-emerging antibiotic for multidrug-resistant
Gram-negative bacterial infections. Lancet Infect Dis, v. 6, p. 589-601, 2006.
LINCOPAN, N.; TRABULSI, L. R. Pseudomonas aeruginosa. In: Trabulsi, L.R., Alterthum,
F. Microbiologia, 4ª ed. Atheneu, São Paulo, p. 359-368, 2004.
LINDEN, P. K.; KUSNE, S.; COLEY, K.; FONTES, P.; KRAMER, D. J.; PATERSON, D.
Use of parenteral colistin for the treatment of serious infection due to antimicrobial-
resistant Pseudomonas aeruginosa. Clin Infect Dis, v. 37, p. 154–160, 2003.
LIVERMORE, D. M. Multiple mechanisms of antimicrobial resistance in Pseudomonas
aeruginosa: our worst nightmare? Clin Infect Dis, v. 34, p. 634-640, 2002.
LIVERMORE, D. M. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob
Chemother, v. 47, p. 247-250, 2001.
MCGOWAN JR, J. E. Resistance in nonfermenting Gram-negative bacteria: Multidrug
resistance to the maximum. Am J Med, v. 34, Suppl. 5, p. 29-37, 2006.
MESAROS, N.; NORDMANN, P.; PLESIAT, P.; ROUSSEL-DELVALLEZ, M.; VAN
ELDERE, J.; GLUPCZYNSKI, Y.; VAN LAETHEM, Y.; JACOBS, F.; LEBECQUE,